Source Count: 9 | Weighted Score: 22 | Source Confidence: [3/5] | Primary Tier: 1 | Last Updated: March 11, 2026
Keywords: RNA interference, RNAi, siRNA, miRNA, gene silencing, Fire, Mello, Dicer, RISC, Argonaute, post-transcriptional regulation
Category Tags: molecular-biology, genetics, RNA, gene-regulation, therapeutics
Cross-References: Z_1_15 — Long Non-Coding RNA · Z_5_08 — DNA

QUICK SUMMARY

RNA interference (RNAi) — the process by which small double-stranded RNA molecules silence gene expression by targeting complementary messenger RNA (mRNA) for degradation or translational repression — is one of the most important discoveries in molecular biology of the past three decades. The phenomenon was first described by Andrew Fire and Craig Mello in 1998 (Nature), who showed that injecting double-stranded RNA (dsRNA) into the nematode Caenorhabditis elegans produced potent and specific silencing of genes with complementary sequences — far more effectively than antisense RNA alone. This discovery earned them the 2006 Nobel Prize in Physiology or Medicine — one of the fastest Nobel recognitions in history (only 8 years from publication to prize). The mechanism involves two classes of small RNA: (1) siRNAs (small interfering RNAs) — ~21-nucleotide duplexes generated by the enzyme Dicer from long dsRNA, which guide the RISC (RNA-Induced Silencing Complex) to perfectly complementary mRNA targets for cleavage and degradation; and (2) miRNAs (microRNAs) — endogenous ~22-nucleotide RNAs encoded in the genome that regulate gene expression through imperfect base-pairing with target mRNAs, typically causing translational repression and/or mRNA destabilization. The human genome encodes ~2,600 mature miRNAs, which collectively regulate an estimated 60% of all protein-coding genes — making miRNAs one of the most pervasive mechanisms of post-transcriptional gene regulation. RNAi has been transformative as a research tool (loss-of-function genetics by gene knockdown), as a therapeutic platform (the first RNAi drug, patisiran, was FDA-approved in 2018 for hereditary transthyretin amyloidosis), and as a window into the fundamental biology of gene regulation by small non-coding RNAs.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 Discovery of RNAi

• Fire and Mello (1998): injected dsRNA corresponding to specific genes into C. elegans; observed potent, specific, and heritable (for a few generations) gene silencing — far more effective than single-stranded sense or antisense RNA; coined the term "RNA interference"
• Key properties: dsRNA trigger → catalytic/amplified silencing (substoichiometric amounts of dsRNA suffice) → sequence-specific → systemic spread (in C. elegans, silencing spreads between tissues)
• Nobel Prize in Physiology or Medicine, 2006: Fire and Mello

1.2 Molecular Mechanism

• siRNA pathway: long dsRNA (from viruses, transposons, or experimental introduction) → cleaved by Dicer (RNase III family enzyme) into ~21-nt siRNA duplexes → one strand ("guide strand") is loaded into RISC (RNA-Induced Silencing Complex, with Argonaute protein at its core) → guide strand directs RISC to perfectly complementary mRNA → Argonaute cleaves the target mRNA ("slicer" activity) → mRNA degraded → gene silenced
• miRNA pathway: primary miRNA transcripts (pri-miRNAs) → processed in the nucleus by Drosha (with DGCR8) into ~70-nt precursor miRNAs (pre-miRNAs) → exported to cytoplasm → processed by Dicer into ~22-nt miRNA duplexes → loaded into RISC → guide strand directs RISC to partially complementary sites (typically in the 3' UTR of target mRNAs) → translational repression and/or mRNA deadenylation and decay

1.3 miRNAs in Gene Regulation

• The human genome encodes ~2,600 mature miRNAs (miRBase); each miRNA can target hundreds of mRNAs; an estimated 60% of protein-coding genes contain conserved miRNA target sites
• miRNAs regulate virtually every biological process: development, differentiation, proliferation, apoptosis, metabolism, immune response
• Dysregulated miRNAs in disease: oncomiRs (miR-21, miR-155 — overexpressed in cancers); tumor-suppressor miRNAs (let-7, miR-34 — downregulated in cancers); circulating miRNAs as diagnostic biomarkers

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 RNAi Therapeutics

• Patisiran (Alnylam Pharmaceuticals, 2018): first FDA-approved RNAi therapeutic — siRNA targeting transthyretin (TTR) mRNA, delivered via lipid nanoparticles to hepatocytes; treats hereditary transthyretin amyloidosis with polyneuropathy
• Givosiran (2019), lumasiran (2020), inclisiran (2020, 2021): subsequent RNAi drugs approved for acute hepatic porphyria, primary hyperoxaluria type 1, and hypercholesterolemia (respectively)
• Delivery challenge: the major obstacle for RNAi therapeutics — naked siRNAs are rapidly degraded by nucleases, poorly taken up by cells, and can trigger innate immune responses; current delivery strategies include lipid nanoparticles (LNPs) and GalNAc (N-acetylgalactosamine) conjugation for liver targeting

2.2 Evolutionary Function: Defense Against Viruses and Transposons

• RNAi likely evolved as an antiviral defense mechanism — many RNA viruses generate dsRNA intermediates during replication, which are recognized and processed by Dicer to generate siRNAs that target and destroy viral RNA; this function is well-documented in plants, insects, and nematodes
• In mammals, the interferon-based innate immune system largely supplanted RNAi as the primary antiviral defense, but the RNAi machinery was co-opted for endogenous gene regulation via the miRNA pathway and for transposon silencing via piRNAs (in the germline)

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 RNAi Therapeutics Beyond the Liver

• Effective systemic delivery of siRNAs to tissues beyond the liver (brain, heart, lung, muscle, tumors) remains a major unmet challenge — while various nanoparticle, exosome, and conjugate strategies are under development, robust extrahepatic RNAi delivery at therapeutic doses has not yet been achieved in the clinic

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Dietary miRNAs Regulating Human Genes

• [CONTROVERSIAL] The 2012 claim (Zhang et al., Cell Research) that plant miRNAs from dietary rice could enter the mammalian bloodstream and regulate human gene expression generated significant interest but has been largely unsubstantiated by follow-up studies — most evidence suggests that dietary uptake of exogenous miRNAs at functionally relevant levels is minimal or artifactual

COUNTER-ARGUMENTS

• Systemic RNAi delivery challenge: While RNAi therapeutics have achieved clinical success for liver targets (patisiran for ATTR amyloidosis, givosiran for acute hepatic porphyria), delivery of siRNAs to non-liver tissues remains the central unsolved challenge — lipid nanoparticles and GalNAc conjugates efficiently target hepatocytes, but delivering RNAi to the CNS, tumors, or other organs at therapeutic doses without off-target effects is an active area of research with limited success so far
• miRNA target prediction accuracy: Computational miRNA target prediction suffers from high false-positive rates — Bartel (2009, 2018) has emphasized that most predicted targets are not physiologically relevant, and that the majority of miRNA regulation involves modest (less than 2-fold) expression changes at individual targets. The biological significance of the long tail of weakly repressed targets is debated
• Mammalian antiviral RNAi: Whether RNAi functions as an antiviral defense in mammalian somatic cells (as it does in plants, insects, and nematodes) remains contested — tenOever (2017) argued that mammals primarily rely on the interferon system and that antiviral RNAi plays at best a minor role in adult mammalian immunity, while Ding and colleagues have presented evidence for functional antiviral RNAi in mammalian stem cells

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Fire, Andrew, et al | 1998 | "Potent and Specific Genetic Interference by Double-Stranded RNA in Caenorhabditis elegans" | Nature | ∅ | 391::806–811 | ∅ | ∅ | doi:10.1038/35888 | ∅ | ∅ | ∅
2. Bartel, David P. | 2004 | "MicroRNAs: Genomics, Biogenesis, Mechanism, and Function" | Cell | ∅ | 116.2::281–297 | ∅ | ∅ | doi:10.1016/s0092-8674(04)00045-5 | ∅ | ∅ | ∅
3. Hannon, Gregory J | 2002 | "RNA Interference" | Nature | ∅ | 418::244–251 | ∅ | ∅ | doi:10.1038/418244a | ∅ | ∅ | ∅
4. Elbashir, Sayda M., et al | 2001 | "Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells" | Nature | ∅ | 411::494–498 | ∅ | ∅ | doi:10.1038/35078107 | ∅ | ∅ | ∅
5. Adams, David, et al | 2018 | "Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis" | New England Journal of Medicine | ∅ | 379.1::11–21 | ∅ | ∅ | doi:10.1016/j.neurol.2018.01.085 | ∅ | ∅ | ∅
6. Bartel, David P | 2018 | "Metazoan MicroRNAs" | Cell | ∅ | 173.1::20–51 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
7. Meister, Gunter; Thomas Tuschl | 2004 | "Mechanisms of Gene Silencing by Double-Stranded RNA" | Nature | ∅ | 431::343–349 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
8. Bernstein, Emily, et al | 2001 | "Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference" | Nature | ∅ | 409::363–366 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
9. Friedman, Robin C., et al | 2009 | "Most Mammalian mRNAs Are Conserved Targets of MicroRNAs" | Genome Research | ∅ | 19.1::92–105 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: March 11, 2026

Corrections

• 1 truncated DOI in the bibliography reassembled — Elsevier identifiers of the form 10.1016/0004-6981(72)90076-5 contain a parenthesised year, and an upstream parse treated the opening bracket as a field break: each DOI was cut short and its tail ()90076-5) left stranded in a neighbouring column. The two halves were rejoined from this same line — it was then confirmed to resolve against Crossref before being written, so no identifier was reconstructed on faith. Repaired: 10.1016/s0092-8674(04)00045-5. Corpus hygiene campaign, Phase 4, 2026-07-29.

• Cross-references — removed this document's own entry (Z_4_14) from its Cross-References list. A document cannot be a cross-reference to itself; the entry conveyed nothing and inflated the reference count. No other target was altered. Corpus hygiene campaign, Phase 4, 2026-07-29.